<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123484</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1702</org_study_id>
    <nct_id>NCT03123484</nct_id>
  </id_info>
  <brief_title>β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC</brief_title>
  <official_title>β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidermal Growth Factor Receptor tyrosine-kinase inhibitors （EGFR-TKIs）, including
      gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non small
      cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially
      sensitive to the drugs eventually become resistance. In this study, the investigators aim to
      explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung
      cancer with EGFR-TKI resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including
      gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non-small
      cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially
      sensitive to the drugs eventually become resistance. Beta-elemene, a natural plant drug
      extracted from Curcuma wenyujin, has been used as an antitumor drug for different tumors,
      including NSCLC via mechanism that inhibits Ras/Mapk signaling and cell cycle progression.In
      this study, the investigators aim to explore the efficacy of beta-elemene, combining with
      EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance.

      main objectives: progression-free survival (PFS) ratio in 12 week the secondary goal:
      Objective Response Rate （ORR）
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS ratio in 12 week</measure>
    <time_frame>12 week</time_frame>
    <description>progression free survival ratio in 12 week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OR Rate</measure>
    <time_frame>12 week</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>β-elemene+EGFR TKI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGFR TKI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>β-elemene</intervention_name>
    <description>β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days</description>
    <arm_group_label>β-elemene+EGFR TKI</arm_group_label>
    <other_name>elemene liposomes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)</intervention_name>
    <description>EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual</description>
    <arm_group_label>β-elemene+EGFR TKI</arm_group_label>
    <arm_group_label>EGFR TKI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Obtain of informed consent.

          2. Histologically or cytologically confirmed, inoperable, recurrence or metastasis
             advanced non-small cell lung cancer (TNM Stage ⅢB or stage Ⅳ), took EGFR-TKI longer
             than 6 months and appeared disease progression.

          3. At least one measurable lesion (helical CT scan long diameter ≥10mm, meet the
             requirements of the standard Response Evaluation Criteria In Solid Tumors（RESCIST）
             version 1.1).

          4. Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :0-2.

          5. Aged from 18 to 75 years (18 and 75 years are included).

          6. Life expectancy ≥12 weeks.

          7. Adequate bone marrow reserve and organ function as follows:

             Absolute neutrophils count (ANC) ≥1.5 x 10 to the 9th power/L (band neutrophil and
             segmented neutrophil), platelets &gt; 100 x 10 to the 9th power/L and Hb≥90g/L.

             Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN).

             Alkaline phosphatase (AP), alanine transaminase (ALT) and aspartate transaminase (AST)
             less than or equal to 3.0 times ULN (or less than or equal to 5 times ULN in case of
             known liver involvement.

             Renal: Serum Creatinine less than or equal to 1.25 times upper limit of normal (ULN).

          8. Females of child-bearing potential must have negative serum pregnancy test. Sexually
             active males and females (of childbearing potential) willing to practice contraception
             during the study.

        Exclusion Criteria:

          1. Do not meet the above criteria.

          2. Unhealed toxicity of prior anti-cancer treatment (CTCAE Level 1) or surgery.

          3. Symptomatic Central Nervous System (CNS) metastases.

          4. Clinical uncontrolled active infection, such as acute pneumonia, active hepatitis B or
             C (prior hepatitis B history, despite medication treatment control or not, HBV
             DNA≥500copies or ≥100IU/ml), etc.

          5. Prior other malignant disease in 5 years (except carcinoma in situ of cervix, or non
             melanoma skin cancers, or localized prostate cancer with Gleason ≤6).

          6. Take part in new drug clinical trials within one month or taking part in a trial now.

          7. Pregnant or lactating woman.

          8. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu yunpeng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Department of Medical Oncology,The First Hospital of China Medical University Affiliation: China Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu yunpeng, PhD</last_name>
    <phone>86 24 83282312</phone>
    <email>cmu_trial@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jin bo, PhD</last_name>
    <phone>86 24 83282542</phone>
    <email>jb_cmu@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Xu XW, Yuan ZZ, Hu WH, Wang XK. [Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer]. Zhongguo Zhong Yao Za Zhi. 2013 May;38(9):1430-7. Chinese.</citation>
    <PMID>23944083</PMID>
  </reference>
  <reference>
    <citation>Li QQ, Wang G, Huang F, Li JM, Cuff CF, Reed E. Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs. Med Oncol. 2013 Mar;30(1):488. doi: 10.1007/s12032-013-0488-9. Epub 2013 Feb 9.</citation>
    <PMID>23397083</PMID>
  </reference>
  <reference>
    <citation>Liu J, Hu XJ, Jin B, Qu XJ, Hou KZ, Liu YP. β-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells. J Pharm Pharmacol. 2012 Jan;64(1):146-53. doi: 10.1111/j.2042-7158.2011.01371.x. Epub 2011 Oct 27.</citation>
    <PMID>22150682</PMID>
  </reference>
  <reference>
    <citation>Matsuoka H, Kaneda H, Sakai K, Koyama A, Nishio K, Nakagawa K. Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs. Clin Lung Cancer. 2017 Jan;18(1):e85-e87. doi: 10.1016/j.cllc.2016.08.004. Epub 2016 Oct 4.</citation>
    <PMID>28341110</PMID>
  </reference>
  <reference>
    <citation>Passiglia F, Listì A, Castiglia M, Perez A, Rizzo S, Bazan V, Russo A. EGFR inhibition in NSCLC: New findings…. and opened questions? Crit Rev Oncol Hematol. 2017 Apr;112:126-135. doi: 10.1016/j.critrevonc.2017.02.009. Epub 2017 Feb 16. Review.</citation>
    <PMID>28325254</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director of Department of Medical Oncology,The First Hospital of China Medical University Affiliation: China Medical University, China</investigator_title>
  </responsible_party>
  <keyword>beta-elemene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

